Skip to content
J B Chemicals & Pharmaceuticals logo

J B Chemicals & Pharmaceuticals

506943 BSE
Price unavailable
View as Markdown
MCP
Close 16 Jul 2026 ₹2,408.90 +717.10 +42.4% since 6 Nov 2025
Start ₹1,691.80

Key Fundamentals

Price-based figures · EPS basis: Consolidated · TTM

ROCE
25.40%
Debt to Equity
0.00
EPS (TTM)
₹45.17
Book Value
—
Market Cap
—
P/E (TTM)
—
P/B
—
ROE
18.90%
Dividend Yield
0.91%
EBITDA
₹1,168 Cr
52W High
—
52W Low
—

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

63 Good

Data confidence 96/100

Category scores

Quality
67
Strong
Returns, margins, earnings quality 25% weight
Valuation
55
Good
Cheap vs sector & own history 20% weight
Growth
32
Poor
Sales & profit trajectory 15% weight
Financial Health
75
Strong
Solvency, leverage, coverage 15% weight
Momentum
87
Strong
Trend strength, vol-adjusted 15% weight
Ownership
59
Good
FII/DII/promoter flows 10% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 40.3%
  • Promoter holding has increased by 1.25% over last quarter.

Weaknesses

3
  • Stock is trading at 9.30 times its book value
  • Promoter holding has decreased over last 3 years: -5.06%
  • Working capital days have increased from 86.6 days to 126 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3412
OscillatorsBullish144
Moving AveragesStrong Bullish208

Key readings

RSI (14)
60.96
Neutral
MACD (12,26,9)
72.22
Bullish
SMA (50)
2,241.45
Bullish
SMA (200)
1,965.87
Bullish

As of , the latest day with price data, so these readings are not current.

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
10Y+13.11%
5Y+15.22%
3Y+9.62%
1Y+5.87%

Net profit

Net profit growth by window
10Y+15.84%
5Y+9.57%
3Y+20.03%
1Y+7.42%

Operating cash flow

Operating cash flow growth by window
10Y+17.53%
5Y+17.45%
3Y+3.99%
1Y−21.95%

Operating margin· change in pp

Operating margin growth by window
10Y+9.67 pp
5Y−0.72 pp
3Y+4.59 pp
1Y+0.35 pp

Trailing twelve months: The last four quarters end with the latest fiscal year, which the 1Y column covers.

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,344 Cr
Mar 2018₹1,408 Cr
Mar 2019₹1,643 Cr
Mar 2020₹1,775 Cr
Mar 2021₹2,043 Cr
Mar 2022₹2,424 Cr
Mar 2023₹3,149 Cr
Mar 2024₹3,484 Cr
Mar 2025₹3,918 Cr
Mar 2026₹4,148 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹184 Cr
Mar 2018₹139 Cr
Mar 2019₹194 Cr
Mar 2020₹272 Cr
Mar 2021₹449 Cr
Mar 2022₹386 Cr
Mar 2023₹410 Cr
Mar 2024₹553 Cr
Mar 2025₹660 Cr
Mar 2026₹709 Cr

AI Analysis — Bull vs Bear

Generated 13 Jul 2026
AI opinion · based on fundamentals
Risk medium

J B Chemicals & Pharmaceuticals trades at a market cap of ₹39,233 Cr with a PE of 55.2x and PB of 9.4x, reflecting premium valuations. The company has delivered consistent 19% ROE over 3 and 5 years with a near debt-free balance sheet, though TTM sales growth has decelerated to 6% from a 5-year CAGR of 15%.

Bull Case 8
  • Company is almost debt-free, having actively reduced debt, providing financial flexibility for growth investments
  • Consistent ROE of 19% maintained over 1-year, 3-year, and 5-year periods, indicating stable capital efficiency
  • Compounded profit growth of 21% over 3 years outpaces sales growth, reflecting margin expansion and operating leverage
  • Healthy dividend payout ratio of 40.3% signals shareholder-friendly capital allocation and earnings confidence
  • Stock CAGR of 51% over 1 year and 34% over 10 years demonstrates sustained long-term wealth creation
  • Promoter holding increased by 1.25% in the last quarter, signalling insider confidence at current levels
  • 10-year compounded sales CAGR of 13% and profit CAGR of 18% reflect a durable, growing franchise
  • 5-year compounded sales CAGR of 15% places the company among faster-growing mid-cap pharma names
Bear Case 7
  • TTM sales growth has decelerated sharply to 6% versus the 5-year CAGR of 15%, raising questions about growth sustainability
  • PB ratio of 9.4x is elevated, meaning much of the future growth is already priced into the stock
  • Working capital days have increased from 86.6 to 126 days, indicating deterioration in cash conversion efficiency
  • Promoter holding has declined by 5.13% over the last 3 years, partially offsetting the recent quarterly increase
  • Dividend yield of just 0.9% offers limited income support relative to the premium valuation being paid
  • The gap between TTM profit growth of 15% and TTM sales growth of 6% may not be sustainable if margin tailwinds fade
  • At 55.2x PE, the stock needs to sustain above-20% profit growth to justify current multiples, a high bar given slowing topline

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

111d ago

TL;DR: J B Chemicals is in the final stages of being absorbed into Torrent Pharmaceuticals, with NCLT approval already secured. There are no notable headwinds in recent news, and institutional block deal activity suggests orderly positioning ahead of the merger completion. The stock's trajectory is now largely tied to the Torrent Pharma integration timeline and RoC filing.

Positives 1
  • NCLT approves Torrent Pharma merger Jul 6

    NCLT Ahmedabad sanctioned the amalgamation of J B Chemicals with Torrent Pharmaceuticals. The scheme becomes effective upon RoC filing, consolidating the company into a larger pharma platform.

Neutral 4
  • ₹49.62 Cr block trade on NSE Jul 16

    Approximately 200,031 shares traded at ₹2,480.70 per share in a block deal worth ₹49.62 crores, indicating institutional-level activity.

  • No encumbrance on JBCHEPHARM shares Jul 2

    Torrent Pharmaceuticals declared no encumbrance on J B Chemicals shares for FY26 under SEBI (SAST) Regulations.

  • Senior executives retire Jun 30 Jun 30

    Pradeep Kumar Singh and Suresh Bhise retired from the company effective June 30, 2026, ceasing to be senior management personnel.

Quarterly Results

₹ Cr

Results for the period ended Jun 2026 were due by 14 Aug 2026 and are not in this table yet.

JBCHEPHARM quarterly results, ₹ crore
Particulars Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
762
896
882
845
862
1,004
1,001
963
949
1,094
1,085
1,065
904
Expenses
599
664
638
621
664
724
730
709
723
793
775
769
703
Operating Profit
164
232
244
223
198
280
271
255
226
301
310
296
201
OPM %
21%
26%
28%
26%
23%
28%
27%
26%
24%
28%
29%
28%
22%
Other Income
5
6
8
7
17
6
10
8
14
15
15
18
−15
Interest
14
12
10
12
9
6
2
3
1
1
1
2
1
Depreciation
32
31
32
34
41
41
42
42
46
43
44
45
50
PBT
122
194
209
184
165
240
237
218
193
272
279
267
135
Tax %
28%
27%
28%
27%
23%
26%
26%
25%
25%
25%
26%
26%
25%
Net Profit
88
142
151
134
126
177
175
162
146
202
208
198
101
EPS (₹)
5.66
9.19
9.72
8.62
8.13
11.39
11.24
10.45
9.36
12.96
13.27
12.63
6.31

Profit & Loss

₹ Cr
JBCHEPHARM profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
1,144
1,210
1,344
1,408
1,643
1,775
2,043
2,424
3,149
3,484
3,918
4,148
Expenses
964
1,004
1,112
1,191
1,337
1,397
1,482
1,881
2,454
2,587
2,886
3,040
Operating Profit
180
206
232
218
306
378
560
543
696
897
1,032
1,107
OPM %
16%
17%
17%
15%
19%
21%
27%
22%
22%
26%
26%
27%
Other Income
11
58
50
37
41
41
112
39
10
37
38
33
Interest
7
11
5
3
5
3
7
5
36
44
12
6
Depreciation
39
41
47
57
56
66
69
73
114
138
171
182
PBT
146
212
230
194
287
349
597
505
555
752
887
952
Tax %
31%
23%
20%
28%
32%
22%
25%
24%
26%
26%
26%
26%
Net Profit
100
163
184
139
194
272
449
386
410
553
660
709
EPS (₹)
5.92
9.58
10.85
8.27
12.06
17.6
28.98
24.93
26.48
35.61
42.36
44.18
Div. Payout %
118%
26%
5%
12%
21%
31%
28%
33%
34%
34%
37%
50%

Balance Sheet

₹ Cr
JBCHEPHARM balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
17
17
17
17
16
15
15
15
15
16
16
16
Reserves
978
1,167
1,347
1,425
1,464
1,420
1,794
2,119
2,465
2,908
3,418
4,143
Borrowings
127
193
49
29
26
29
45
55
572
378
28
4
Other Liabilities
365
270
262
294
286
349
376
412
495
687
804
799
Total Liabilities
1,487
1,648
1,674
1,765
1,792
1,814
2,231
2,601
3,547
3,988
4,265
4,962
Fixed Assets
329
440
679
640
621
651
634
1,277
1,901
2,004
1,968
1,885
CWIP
55
135
4
17
15
16
26
19
55
76
63
74
Investments
552
479
411
434
457
403
678
13
206
388
345
765
Other Assets
552
594
580
674
699
743
894
1,293
1,385
1,519
1,889
2,237
Total Assets
1,487
1,648
1,674
1,765
1,792
1,814
2,231
2,601
3,547
3,988
4,265
4,962

Cash Flow

₹ Cr
JBCHEPHARM cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
127
140
201
123
194
276
315
170
626
801
902
704
Investing
−112
−26
−45
−21
−28
24
−231
2
−962
−404
−296
−586
Financing
−1
−100
−184
−60
−156
−306
−87
−138
357
−385
−580
−123
Net Cash Flow
13
15
−28
43
11
−6
−3
34
20
11
27
−5
Free Cash Flow
56
−63
48
94
153
205
315
−529
−138
540
783
623
CFO/EBITDA
91
94
107
75
85
97
81
56
104
104
107
87

Ratios

JBCHEPHARM financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
84
82
72
78
68
71
70
84
67
72
76
69
Inventory Days
122
146
138
145
149
159
181
178
134
155
147
192
Days Payable
63
71
68
75
72
97
97
97
75
110
114
110
Cash Conversion Cycle
143
158
142
148
146
133
153
164
127
117
109
151
Working Capital Days
16
38
75
93
91
81
91
122
81
55
79
126
ROCE %
13%
15%
14%
11%
18%
23%
33%
23%
22%
25%
26%
25%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view J B Chemicals & Pharmaceuticals insights

70 extracted metrics across FY11–FY26.

Shareholding Pattern

As of Mar 2026

  • Promoters 48.80%
  • DIIs 21.38%
  • FIIs 16.33%
  • Public 13.48%

Pledge data not available

Change vs previous quarter

Documents

Frequently Asked Questions about J B Chemicals & Pharmaceuticals

What does J B Chemicals & Pharmaceuticals Ltd do?
J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals…
Where is J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) listed?
J B Chemicals & Pharmaceuticals Ltd trades under code 506943 on the BSE.
Which sector does J B Chemicals & Pharmaceuticals Ltd belong to?
J B Chemicals & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Does J B Chemicals & Pharmaceuticals Ltd pay dividends?
J B Chemicals & Pharmaceuticals Ltd has a dividend yield of 0.91%.
What is the Return on Equity (ROE) of J B Chemicals & Pharmaceuticals Ltd?
J B Chemicals & Pharmaceuticals Ltd reported a return on equity of 18.90%. Its debt-to-equity ratio is 0.00.

Company Information

J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally.

Website jbpharma.com
Listed 29 Apr 2003
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JBCHEPHARM.md for J B Chemicals & Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month